BBA
UROV

Baker Bros. Advisors’s Urovant Sciences Ltd. UROV Stock Holding History

Baker Bros. Advisors’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-978,505
Closed -$9.14M – 131
2020
Q3 		$9.14M Sell
978,505
-21,495
-2% -$191K 0.04% 68
2020
Q2 		$9.84M Hold
1,000,000
– – 0.04% 61
2020
Q1 		$9.22M Hold
1,000,000
– – 0.06% 51
2019
Q4 		$15.5M Buy
+1,000,000
New +$10.8M 0.08% 48

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
OCM
Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Baker Bros. Advisors's UROV Position: Q4 2020 in Review

Baker Bros. Advisors sold out of Urovant Sciences Ltd. (UROV) in Q4 2020, closing a stake of 978,505 shares — an estimated $9.14M sold.

Baker Bros. Advisors first reported a position in UROV in Q4 2019 and held it in 4 quarters. The position peaked at $15.5M in Q4 2019. 41 funds tracked by Wall St. Rank hold UROV as of Q4 2020.

  • Baker Bros. Advisors reported no remaining Urovant Sciences Ltd. position as of Q4 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 978,505 Urovant Sciences Ltd. shares in Q4 2020, an estimated $9.14M.
  • Baker Bros. Advisors first reported a position in Urovant Sciences Ltd. in Q4 2019 and held it in 4 quarters.
  • Baker Bros. Advisors's Urovant Sciences Ltd. position peaked at $15.5M in Q4 2019.
  • 41 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2020.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.